ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza ups ʟ-asparaginase for Servier

by Rick Mullin
August 14, 2020 | APPEARED IN VOLUME 98, ISSUE 31

 

Lonza is expanding microbial manufacturing with a new facility in Visp, Switzerland, that will serve the French drugmaker Servier and other customers. In particular, the facility will boost output of l-asparaginase, which Lonza has made for Servier since 2009. The enzyme is the basis of Servier’s chemotherapy for acute lymphoblastic leukemia, a white blood cell cancer. The plant, scheduled to open by the end of 2022, should create 100 jobs, Lonza says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment